With rights to a novel gene that it believes will help protect and repair damaged heart tissue and an adeno-associated virus (AAV) gene therapy delivery system, NanoCor Therapeutics is currently developing preclinical data to support the use of its gene therapy to treat chronic heart failure patients awaiting a heart transplant.
870 Martin Luther King Jr. Blvd.
Chapel Hill, NC 27514
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
Oral RNA splicing modulator has gone into a Phase II/III trial
